Cisplatin Plus Research Articles

Cisplatin Plus Oral Etoposide in the Treatment of Patients with Advanced Small Cell Lung Cancer

Etoposide is a highly schedule-dependent drug. We investigated combination chemotherapy of oral etoposide and intravenous cisplatin for small cell lung cancer (SCLC). Fifty-seven patients with SCLC with extensive disease (ED) or limited disease (LD) with pleural effusion registered in the 21 institutions of the Japan Clinical Oncology Group were treated with oral etoposide 40 mg/m2/d for 21 days and cisplatin 80 mg/m2 on day 1 of every 28-period day. The entry period was between February 1992 and August 1995. The actual percentages of patients treated with etoposide were 93.6, 89.5, 92.3 and 96.9% in the first, second, third and fourth cycles, respectively. Nine patients (15.8%) achieved a complete response resulting in an overall response rate of 82.5% (95% confidence interval, 70.1-91.3%). Leukopenia and thrombocytopenia of grade 3 or 4 were observed in 36 (49.1%) and 8 (14.0%) patients, respectively. Anemia of grade 3 or 4 occurred in 28 (49.1%) patients. Nausea, vomiting, anorexia and alopecia were common adverse events. One patient died of hemoptysis due to grade 4 thrombocytopenia. The mean survival time was 47.0 weeks. This dose and schedule of administration of etoposide in combination with cisplatin are considered to be clinically active. However, prolonged gastrointestinal toxicity of oral etoposide was a problem in comparison with the standard etoposide platinum regimen given by intravenous administration.

Phase II Trial of High-Dose Cisplatin Plus Ifosfamide as First-Line Followed by Carboplatin as Second-Line Treatment in Epithelial Ovarian Carcinoma

Background.In a previous study of combined platinum and ifosfamide we found a pathologic complete response rate of 42%. The present study was to test whether the high response rate could be reproduced or even improved by combining high-dosecis-platinum and increased dose of ifosfamide.Methods.Forty-two previously untreated ovarian cancer patients were included in the study. Cisplatin 50 mg/m2and ifosfamide 2000 mg/m2together with mesna 1200 mg/m2were given daily, Day 1–3 every 4 weeks for six cycles, followed by second-look laparotomy. In the event of residual disease carboplatin was given every 4 weeks for a further six cycles.Results.The pathologic complete response rate was 20% (8 of 41). Five of 26 patients achieved a further response on carboplatin. Hematologic and nonhematologic toxicity caused dose reduction in more than 90 and 50% of the patients, respectively.Conclusion.The results of this high-dose regimen equals those obtained with conventional, far less toxic, regimens. Only patients with potentially platinum-sensitive tumors achieved further response when crossed over to the analogue, which may indicate that prolonged treatment is better than increased dose. A randomized trial is still needed to assess the importance of dose intensity in ovarian cancer.

シスプラチン・ビンデシンによる肺非小細胞癌化学療法時の悪心，おう吐の予防 グラニセトロン単独とグラニセトロン，中等量メチルプレドニゾロン併用に関する無作為化比較試験

シスプラチン・ビンデシンによる肺非小細胞癌化学療法時の悪心，おう吐の予防 グラニセトロン単独とグラニセトロン，中等量メチルプレドニゾロン併用に関する無作為化比較試験

Cisplatin plus epirubicin and etoposide followed by irradiation plus lonidamine in stage III nonsmall cell lung cancer.

Forty-seven patients with stage III nonsmall cell lung cancer (NSCLC) were treated with the sequential administration of combination chemotherapy consisting of cisplatin, epirubicin and etoposide and of irradiation plus lonidamine. The response rate was 49% after chemotherapy with an improvement of 14% after radiation therapy and lonidamine. The median survival was around 15 months for responders and 9 months for nonresponders. Toxicity was moderate and acceptable. It is concluded that this schedule is active in the treatment of NSCLC.

Improved Therapeutic Index of Carboplatin Plus Cyclophosphamide Versus Cisplatin Plus Cyclophosphamide

There was an error in Table 9 of the report "Improved Therapeutic Index of Carboplatin Plus Cyclophosphamide Versus Cisplatin Plus Cyclophosphamide: Final Report by the Southwest Oncology Group of a Phase III Randomized Trial in Stages III and IV Ovarian Cancer" by Alberts et al (J Clin Oncol 10:706–717, 1992). The dosage of cisplatin given in the table for the report by Kato et al (cited as reference 21) should have been 50 mg/m2. The table is reprinted here correctly in its entirety: Please see the PDF for Table.

A Randomized Trial Comparing Cisplatin Plus Cyclophosphamide Versus Cisplatin, Doxorubicin, and Cyclophosphamide in Advanced Ovarian Cancer

In the article by Conte et al, "A Randomized Trial Comparing Cisplatin Plus Cyclophosphamide Versus Cisplatin, Doxorubicin, and Cyclophosphamide in Advanced Ovarian Cancer" (Journal of Clinical Oncology 4:965–971, 1986), an error was made in the abstract on page 965 that altered the meaning of a sentence. The correct sentence appears below. After primary surgery, 125 patients with epithelial ovarian cancer (International Federation of Gynaecology and Obstetrics [FIGO] 1c + IIb + IIc = 22 patients, FIGO III = 82 patients, FIGO IV = 21 patients) were randomly allocated to receive PC (cisplatin 50 mg/m2 + cyclophosphamide 600 mg/m2 on day 1 every 28 days) or PAC (PC + doxorubicin 45 mg/m2).